Olav Bergheim

Olav is the Founder and Managing Director of Fjord Ventures LLC, a life sciences accelerator company whose portfolio includes Adagio Medical, Inc.; Allegro Medical, Inc.; Anaxiom Corporation; Kato Pharmaceuticals, Inc.; Metronom Health, Inc.; Prelude Corporation; Sonendo, Inc.; Volante Diagnostics, Inc.; and YAP Therapeutics, Inc. Each of these companies was founded by Olav.

Previously, Olav was General Partner of Domain Associates, which he joined in 1995 and was charged with forming and providing active management to new life sciences companies. There he established the Company Creation Initiative that led to the formation of several companies, including VenPro; 3F Therapeutics (acquired by Medtronic); Vessix Vascular (acquired by Boston Scientific); Volcano Therapeutics (acquired by Phillips); and Glaukos Corporation.

Earlier, Olav spent 18 years in general management positions at Baxter Healthcare Corporation, serving as Corporate Group Vice President and also President of Baxter’s Cardiovascular Group (now: Edwards LifeSciences). His prior positions with Baxter included President of Immunotherapy Worldwide, President BioTech Europe, and President of Baxter in Germany and General Manager of the Nordic area.